Weight extremes, a body-mass index (BMI) either very underweight or obese, are associated with increased all-cause mortality.  Mortality attributable to obesity is caused by many secondary conditions like metabolic disorders and cardiovascular (CV) disease. Enter the glucagon-like peptide-1 (GLP-1) receptor agonists—initially approved in the treatment of type 2 diabetes— which induce significant weight loss regardless of diabetes status.  But can a weight loss drug decrease CV mortality?

Guest Authors:  Gregory Castelli, PharmD, BCPS, BC-ADM, CDCES and Drake Meaney, PharmD, BCPS

Music by Good Talk